Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3 …
CW Hanke, KR Beer, E Stockfleth, J Wu… - Journal of the American …, 2010 - Elsevier
BACKGROUND: Imiquimod 5% cream is approved as a 16-week regimen for the treatment
of actinic keratoses involving a 25-cm2 area of skin. OBJECTIVE: We sought to evaluate
imiquimod 2.5% and 3.75% creams for short-course treatment of the entire face and scalp.
METHODS: In two identical studies, adults with 5 to 20 lesions were randomized to placebo,
or imiquimod 2.5% or 3.75% cream (1: 1: 1). Up to two packets (250 mg each) were applied
per dose once daily for two 3-week treatment cycles, with a 3-week, no-treatment interval …
of actinic keratoses involving a 25-cm2 area of skin. OBJECTIVE: We sought to evaluate
imiquimod 2.5% and 3.75% creams for short-course treatment of the entire face and scalp.
METHODS: In two identical studies, adults with 5 to 20 lesions were randomized to placebo,
or imiquimod 2.5% or 3.75% cream (1: 1: 1). Up to two packets (250 mg each) were applied
per dose once daily for two 3-week treatment cycles, with a 3-week, no-treatment interval …